An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors

被引：8
|
作者：
Rodon, J. [1 ]
Li, J. [2 ]
Xue, J. [2 ]
Diao, Y. [3 ]
Xu, Y. [3 ]
Liu, G. [3 ]
Rao, C. [3 ]
Fan, B. [3 ]
Cheng, Y. [3 ]
Wang, J. [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Early Drug Dev, Houston, TX 77030 USA
[2] Shanghai East Hosp, Oncol Dept, Shanghai, Peoples R China
[3] Sichuan Kelun Biotech Biopharmaceut Co Ltd, Clin Res Ctr, Chengdu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
514O
引用
收藏
页码：S585 / S585
页数：1
相关论文
共 50 条
  • [31] ATLAS: A Phase II, open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma
    Grivas, Petros
    Teo, Min Yuen
    Vogelzang, Nicholas
    Alva, Ajjai
    Zakharia, Yousef
    Adra, Nabil
    Drakaki, Alexandra
    Hussain, Arif
    Morales-Barrera, Rafael
    Necchi, Andrea
    Rodriguez-Vida, Alejo
    Feyerabend, Susan
    Gupta, Sumati
    Josephs, Debra H.
    Loriot, Yohann
    Srinivas, Sandy
    Wride, Kenton
    Thomas, Daleen
    Dusek, Rachel
    Simmons, Andrew D.
    Nepert, Dale
    Chowdhury, Simon
    CANCER RESEARCH, 2019, 79 (13)
  • [32] Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors
    Balmana, Judith
    Tung, Nadine M.
    Isakoff, Steven J.
    Grana, Begona
    Ryan, Paula D.
    Rafi, Rezvan
    Tracy, Michael
    Winer, Eric
    Baselga, Jose
    Garber, Judy Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors
    Pierre Maison-Blanche
    Shaker Dakhil
    Ari Baron
    Sylvie Rottey
    Fred Millard
    Gedske Daugaard
    Jean-Pascal Machiels
    William Conkright
    Sunil Sharma
    Patricia M. M. B. Soetekouw
    Jeffrey Yachnin
    Lisa Sengeløv
    Peter Van Veldhuizen
    Sanjiv S. Agarwala
    Dorothée Sémiond
    Mustapha Chadjaa
    Liji Shen
    James L. Wade
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 1241 - 1252
  • [34] An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors
    Maison-Blanche, Pierre
    Dakhil, Shaker
    Baron, Ari
    Rottey, Sylvie
    Millard, Fred
    Daugaard, Gedske
    Machiels, Jean-Pascal
    Conkright, William
    Sharma, Sunil
    Soetekouw, Patricia M. M. B.
    Yachnin, Jeffrey
    Sengelov, Lisa
    Van Veldhuizen, Peter
    Agarwala, Sanjiv S.
    Semiond, Dorothee
    Chadjaa, Mustapha
    Shen, Liji
    Wade, James L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (06) : 1241 - 1252
  • [35] A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor
    George, Suzanne
    Heinrich, Michael C.
    Somaiah, Neeta
    Oppelt, Peter
    McLeod, Robert
    Nishioka, Satoshi
    Kundu, Madan G.
    Qian, Xiaozhong
    Kumar, Prasanna
    Laadem, Abderrahmane
    Lau, Yvonne
    Tran, Brittany P.
    Fallon, Maura
    Dosunmu, Ololade
    Shi, Julia
    Naito, Yoichi
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3659 - 3667
  • [36] First-in-human study of PM14 in patients with advanced solid tumors.
    Vieito, Maria
    Aix, Santiago Ponce
    Paz-Ares, Luis G.
    Bahleda, Rastilav
    Massard, Christophe
    Agreda, Leyre
    Banus, Eva
    Fernandez, Cristian Marcelo
    Cristoveanu, Elena Y.
    Corral, Gema
    Llanero, Lourdes
    Lubomirov, Rubin
    Kahatt, Carmen Maria
    Fudio, Salvador
    Nieto, Antonio
    Cullell-Young, Martin
    Zeaiter, Ali Hassan
    Oberoi, Honey Kumar
    Garralda, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations.
    Janku, Filip
    Kauh, John S.
    Tucci, Christopher
    Yang, Zhao
    Kania, Marek K.
    Alese, Olatunji B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] A Phase 1/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1303 in patients with advanced/metastatic solid tumors
    Hamilton, Erika
    Zhang, Jian
    Liu, Liming
    Gao, Jie
    Shi, Rong
    Liu, Shengxue
    Wei, Gu
    Qiu, Yang
    Moore, Kathleen
    CANCER RESEARCH, 2023, 83 (08)
  • [39] STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions
    Drilon, Alexander
    Sankhala, Kamalesh Kumar
    Liu, Stephen V.
    Cho, Byoung Chul
    Blakely, Collin
    Chee, Cheng E.
    Fakih, Marwan
    Polikoff, Jonathan
    Hornby, Zachary
    Schechet, Lisa
    Luo, David
    Maneval, Edna Chow
    Multani, Pratik S.
    Doebele, Robert C.
    CANCER RESEARCH, 2017, 77
  • [40] A first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumors
    Yun, T.
    Shin, S. J.
    Kim, D-W.
    Yun, C. H.
    Heo, S.
    Hyun, B.
    Kim, Y. S.
    Kim, J. S.
    Moon, Y. W.
    ANNALS OF ONCOLOGY, 2022, 33 : S20 - S20
12345